{"id":390558,"date":"2018-11-09T00:00:00","date_gmt":"2018-11-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2018-biopharma-psoriasis-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-18T11:38:52","modified_gmt":"2026-04-18T11:38:52","slug":"dlsfim0005-2018-biopharma-psoriasis-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2018-biopharma-psoriasis-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Psoriasis | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>)-alpha inhibitors and interleukin (<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>)-12\/23 inhibitor ustekinumab (Janssen\u2019s Stelara) is being challenged by the introduction of the highly effective\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-17 inhibitors. In particular, the uptake of secukinumab (Novartis\u2019s Cosentyx) has been remarkable in the first two years of its launch, but the agent faces competition from the newer\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-17 inhibitors\u2014ixekizumab (Eli Lilly\u2019s Taltz) and brodalumab (Valeant\/LEO Pharma\/Kyowa Hakko Kirin\u2019s Siliq\/Kyntheum\/Lumicef). With the approval and launch of Janssen\u2019s\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-23 inhibitor, guselkumab (Tremfya), another effective drug class has been introduced into this increasingly competitive market. Additionally, the landscape for the established biologics will change further with the increasing availability and use of biosimilars.<\/p>\n<ul>\n<li><strong>How do interviewed\u00a0<abbr data-original-title=\"key opinion leader\" title=\"\">KOL<\/abbr>s view the efficacy and safety of the\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-17 inhibitors (Cosentyx, Taltz, Siliq\/Lumicef, bimekizumab), and where are\/will these agents be positioned in the psoriasis treatment algorithm?<\/strong><\/li>\n<li><strong>What will be the impact of the\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-23 inhibitors (guselkumab, Merck &#038; Co.\/Almirall\/Sun Pharma\u2019s tildrakizumab, AbbVie\/Boehringer Ingelheim\u2019s risankizumab, Eli Lilly\u2019s mirikizumab), and how will they fare in the competitive psoriasis market?<\/strong><\/li>\n<li><strong>How is the oral agent apremilast (Celgene\u2019s Otezla) used for psoriasis treatment, and what are the other promising emerging oral therapies?<\/strong><\/li>\n<li><strong>How fast will the uptake of biosimilars occur in psoriasis, and which brands will experience the most erosion in patient share and sales?<\/strong><\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><b>Markets covered:<\/b>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><b>Primary research:<\/b>\u00a020 country-specific interviews with thought leaders.<\/p>\n<p><b>Epidemiology:<\/b>\u00a0Number of total, diagnosed, and drug-treated prevalent cases of psoriasis; number of diagnosed prevalent cases of psoriasis by severity.<\/p>\n<p><b>Emerging therapies:<\/b>\u00a0Phase II: 14drugs; Phase III\/preregistration: 7 drugs; coverage of select preclinical and Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-390558","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390558\/revisions"}],"predecessor-version":[{"id":576697,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390558\/revisions\/576697"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}